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Incomplete response in late-life depression is
an important public health problem
he aging of the US population is expected to
increase the number of persons aged 65 and older from
35 million (in 2000) to more than 86 million by 2050.
1
These data, together with longer life expectancy and
increased depression rates in recent cohorts,
2 predict an
epidemic of late-life depression (LLD).LLD complicates
medical illnesses
3-7 and increases mortality,
8 disability,
9
and health care utilization.
10 LLD often has poor acute
419
Translational research
T
Copyright © 2008 LLS SAS.  All rights reserved www.dialogues-cns.org
Incomplete response in late-life depression:
getting to remission
Eric J. Lenze, MD; Meera Sheffrin, BA; Henry C. Driscoll, MD, MS;
Benoit H. Mulsant, MD; Bruce G. Pollock, MD, PhD; Mary Amanda Dew,
PhD; Frank Lotrich, MD, PhD; Bernie Devlin, PhD; Robert Bies, PhD;
Charles F. Reynolds III, MD
Keywords: old-age depression; incomplete response; remission; pharmacologic
augmentation; aripiprazole 
Author affiliations: Washington University School of Medicine Department of
Psychiatry, St Louis, MO, USA (Eric J. Lenze); Advanced Center for Interventions
and Services Research for Late-Life Mood Disorders, University of Pittsburgh, PA,
USA (Meera Sheffrin, Henry C. Driscoll, Mary Amanda Dew, Frank Lotrich, Bernie
Devlin, Robert Bies, Charles F. Reynolds III); Center for Addictions and Mental
Health, University of Toronto, Canada (Benoit H. Mulsant, Bruce G. Pollock)
Address for correspondence: Charles F. Reynolds III, MD, Western Psychiatric
Institute and Clinic 1138 O’Hara Street, E1135, Pittsburg, PA 15213, USA
(e-mail: reynolds@upmc.edu)
Incomplete response in the treatment of late-life depression is a large public health challenge: at least 50% of older peo-
ple fail to respond adequately to first-line antidepressant pharmacotherapy, even under optimal treatment conditions.
Treatment-resistant late-life depression (TRLLD) increases risk for early relapse, undermines adherence to treatment for
coexisting medical disorders, amplifies disability and cognitive impairment, imposes greater burden on family caregivers,
and increases the risk for early mortality, including suicide. Getting to and sustaining remission is the primary goal of
treatment, yet there is a paucity of empirical data on how best to manage TRLLD. A pilot study by our group on aripipra-
zole augmentation in 24 incomplete responders to sequential SSRI and SRNI pharmacotherapy found that 50% remitted
over 12 weeks with the addition of aripiprazole, and that remission was sustained in all participants during 6 months of
continuation treatment. In addition to controlled assessment, evidence is needed to support personalized treatment
by testing the moderating role of clinical (eg, comorbid anxiety, medical burden, and executive impairment) and genetic
(eg, selected polymorphisms in serotonin, norepinephrine, and dopamine genes) variables, while also controlling for vari-
ability in drug exposure. Such studies may advance us toward the goal of personalized treatment in late-life depression.
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sant treatment.
11 Thus, new treatment approaches are
needed to increase remission from LLD and to support
evidence-based selection of appropriate interventions at
different points in the course of illness (ie,the right treat-
ment at the right time).
Treatment-resistant depression (TRD) has been defined
as failure to achieve remission with one antidepressant
medication trial,
12-14 or two trials,
15 of adequate dose and
duration.Rates of treatment resistance in randomized
controlled trials in LLD are as high as 77% using selec-
tive serotonin reuptake inhibitors (SSRIs)
16 and range
from 55% to 81% using serotonin/norepinephrine reup-
take inhibitors (SNRIs).
16-19Treatment resistance must be
distinguished from inadequate treatment (eg,short treat-
ment duration preventing late responders from achiev-
ing remission),and misdiagnosis (eg,failing to recognize
dementia,psychosis,or bipolar disorder).Treatment resis-
tance is particularly germane to LLD,for three reasons.
First,high rates of comorbid anxiety and medical illness
contribute to treatment failure.Second,older adults may
have greater pharmacodynamic variability as a result of
genetic variability (eg,at serotonin receptors
20) and age-
or medical illness-related changes in brain structure or
function (eg,decline in serotonin receptors
21,22),interrup-
tions in neurocircuitry integrity from cerebrovascular dis-
ease or prodromal Alzheimer’s disease.
23,24Third,older
adults may have greater pharmacokinetic variability,as a
result of poor adherence (eg, due to cognitive impair-
ment) and metabolic variability (eg,due to age-related
changes in drug metabolism).
25
The serious consequences of persistent depressive symp-
toms in elderly persons include relapse and recurrence,
26-
29 functional disability,
30 and cognitive decline,owing in
part to the impact of long periods of untreated depres-
sion on hippocampal volume.
31 Persisting LLD is also
associated with an increased mortality,
32 including suicide.
Risk for suicide can be reduced with successful treat-
ment.
33,34 Finally,treatment-resistant late-life depression
(TRLLD) is associated with increased caregiver burden
in family members of depressed elders (Martire L,per-
sonal communication,2008).In these ways,incomplete
response in late-life depression and the need to get to
remission are major public health challenges.
Despite this challenge,almost no data exist to guide the
treatment of TRLLD.The best current evidence guiding
intervention for treatment-resistant depression comes
from the Sequenced Treatment Alternatives to Relieve
Depression (STAR*D study
35). However, only a small
minority of subjects who participated in STAR*D were
elderly.Our collaborative group has carried out several
examinations of treatment strategies for TRLLD,includ-
ing open studies of switching from an SSRI to nortripty-
line,
36 venlafaxine,
37 or duloxetine,
38 a stepwise strategy of
bupropion, nortriptyline, or lithium augmentation of
SSRI,
39,40 and electroconvulsive therapy.
41,42 Our findings
suggest that a significant proportion (40% to 50%) of
SSRI nonresponders will respond to these strategies,con-
sistent with a prior open sequential trial.
43 In the only
published placebo-controlled pharmacotherapy trial for
TRLLD,Sunderland et al
44 found that the monoamine
oxidase inhibitor (MAOI) selegiline was efficacious.
However,in a recent randomized comparison of lithium
augmentation and the MAOI phenelzine for TRLLD,
one third of those receiving lithium remitted versus none
receiving phenelzine.
19These two controlled studies suf-
fer from small sample size,short duration,and inclusion
of subjects with psychosis.Thus,beyond the intuitive step
of switching from SSRI to SNRI, there appear to be
almost no controlled data to inform the treatment of
TRLLD in old age.
The relationship of anxiety, comorbid medical illness,
and executive dysfunction to TRLLD
Literature reviews have suggested that anxiety,medical
illness,and executive dysfunction may be key clinical pre-
dictors of treatment resistance in LLD.
37,45
Anxiety
Anxiety is a common cotraveler with LLD.Several stud-
ies have found an increased time to remission, and
reduced remission rate, in LLD when there are either
high levels of anxiety symptoms
46-52 or a comorbid anxi-
ety disorder such as generalized anxiety.
53 Despite numer-
ous studies establishing anxiety as a predictor of treat-
ment resistance in LLD, this relationship is poorly
understood.Mechanisms that may explain this relation-
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Selected abbreviations and acronyms
LLD late-life depression
SRNI serotonin/norepinephrine reuptake inhibitor
SSRI selective serotonin reuptake inhibitor
TRD treatment-resistant depression
TRLLD treatment-resistant late-life depressionship include reduced tolerance of, and adherence to,
medication, or a more severe subtype of depression.
Anxiety in late life is multidimensional, encompassing
worry,panic/fear,somatization,and personality factors
54;
the differential impact of these dimensions on treatment
resistance is largely unstudied.Along these lines,we have
found preliminarily that symptoms of worry,and not fear
or panic,predict both poor short-term outcome in LLD
and poor long-term stability of remission (Andreescu C,
personal communication,2008).Needed is a treatment
trial incorporating examinations of these multiple dimen-
sions that will shed light on the anxiety-depression inter-
face in late life.
Medical burden
Several studies have demonstrated that LLD patients
with greater medical burden have a lower,and slower,
treatment response in LLD (eg, refs 55-57).Although
some studies have not supported a link between medical
burden and treatment outcome,
58,59 our group found that
greater medical burden predicted poorer acute outcome
to antidepressant augmentation (primarily with bupro-
pion or nortriptyline
40) and poorer maintenance out-
comes.
60 One reason may be that medical illnesses seen
in patients with LLD (eg,hypertension,high cholesterol,
diabetes, endocrinologic disease) induce pharmacody-
namic or structural central nervous system changes that
reduce the efficacy of standard antidepressants. Other
possibilities are that medical burden interferes with anti-
depressant adherence and/or increases variability of drug
exposure,thus reducing the impact of antidepressants.
Impairment of executive functioning
Neuropsychological impairment,particularly in executive
functioning,is common and clinically significant in LLD.
61
Several studies have noted a relationship of cognitive
impairment with lower antidepressant response rates,
62-64
though other studies have not found this relationship.
65-67
The discrepancy may result from the variability between
studies in measuring executive functioning,and the cur-
rent consensus in the field is that executive dysfunction is
associated with poorer LLD treatment outcomes with
antidepressants. Treatment resistance in the context of
executive dysfunction is thought to be due to alterations
in neurocircuitry integrity that disrupt the pharmacody-
namics of antidepressants.
68
In summary, the above clinical variables predict poor
antidepressant outcomes in LLD. However, there is
insufficient understanding of how they contribute to
poorer outcomes,and so their clinical utility is limited.
This lack of understanding is part of the gap between
personalized medicine (matching treatment to patients
based upon patient characteristics) and the current trial-
and-error approach to LLD management.
The relationship of genetic and drug exposure 
variability to TRLLD
Functional genetic polymorphisms change the pharma-
codynamics of antidepressant medications;therefore,it
is posited that antidepressant outcomes in LLD can be
predicted by genetic variation in their homologous recep-
tor targets.
69 In other words,functional genetic variation
of the 5-HTT is expected to affect SSRI response,while
variation in the norepinephrine transporter (NET) is
expected to affect SNRI response. One example is the
serotonin transporter linked polymorphic region (5-
HTTLPR) in the promoter of the gene that encodes for
the serotonin transporter (5-HTT),the primary target of
SSRIs.A deletion polymorphism in 5-HTTLPR, the s
allele (s=“short”vs l=“long”),appears to be functional:
it reduces expression of 5-HTT so that individuals with
the s allele have fewer 5-HTTs than those with l/l geno-
type.The association of the s allele with poorer SSRI out-
comes has been demonstrated in LLD,
70 including a study
from our group that was the first to report this associa-
tion in LLD.
20The association appears specific to SSRIs
and was not found with mirtazapine
71 or nortriptyline.
70
In addition,we think that measures of drug exposure are
needed to interpret clinical and genetic findings.
72
Specifically,we think that pharmacokinetic modeling is
important in pharmacogenetic analyses.Supporting this
contention, Lotrich et al
73 found that the 5-HTTLPR s
allele predicted poorer treatment outcome at lower con-
centrations of paroxetine but not at higher concentra-
tions.
Following up on this observation, Lotrich examined
depressed elderly subjects who were treated in an open-
label paroxetine study and who were genotyped (n=110).
Again,there was an interaction between paroxetine con-
centration and 5-HTTLPR genotype on symptomatic
improvement over 12 weeks (F(18,59.5)=1.8; P<0.05):
paroxetine concentrations were correlated with change
in the Hamilton Depression Rating Scale (HAM-D) in
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421subjects with the s allele,but not in subjects homozygous
for the l allele.In other words,the s allele moderated the
impact of the drug.These data demonstrate the impor-
tance of pharmacokinetic data for conducting meaning-
ful pharmacogenetic analyses.This issue is particularly
relevant to geriatrics,as age-related changes in drug elim-
ination amplify drug concentration differences for a
given dose.
Relevance of anxiety, medical burden, executive 
dysfunction, and genetic variability for augmentation
strategies in TRLLD
Comorbid anxiety,medical burden,and executive dys-
function are highly prevalent in TRLLD patients.
Because these variables are associated with poor out-
comes using standard antidepressants,they may identify
patients likely to require more aggressive strategies
including augmentation (as opposed to “staying the
course”).As such,these variables are expected to mod-
erate the efficacy of augmentation (ie, increase drug-
placebo difference).This is consistent with research from
PROSPECT (Prevention of Suicide in Primary Care
Elderly:Collaborative Trial) in which executive dysfunc-
tion moderated the difference between aggressive LLD
management and usual care.
74 A similar moderation
effect has been found with medical comorbidity
60,75 and
comorbid anxiety.
9 Thus, we hypothesize that anxiety,
medical burden,and executive dysfunction are clinical
markers of need for augmentation.
Conversely, it is possible that these variables predict
treatment nonadherence or increased metabolic variabil-
ity resulting in poor outcomes regardless of treatment.
40
This possibility underscores the importance of measur-
ing drug exposure in studies of TRLLD.For example,by
controlling for both the average drug concentration and
the variability of drug exposure,it is possible to deter-
mine the contribution of comorbid medical illness to
treatment efficacy while accounting for drug exposure.
The same logic applies for patients with highly prevalent
genetic polymorphisms. Thus, by using drug exposure
data the effect of clinical and genetic moderators can be
more precisely examined, ultimately reducing the gap
between the potential of personalized medicine and the
current empiric approach for LLD management.In the
next section,we present for heuristic purposes our work
with aripiprazole as a candidate augmentation strategy
for managing incomplete response in LLD and getting to
remission.We present first a pharmacologic and clinical
rationale,followed by pilot data.Finally,we describe the
design of a randomized controlled trial informed by
those data.
Aripiprazole as a potential 
treatment for TRLLD
Aripiprazole is an atypical antipsychotic (or “atypical”)
approved by the Food and Drug Administration to treat
schizophrenia and mania.It has a high D2 receptor affin-
ity,and as a partial agonist,it has a higher affinity for the
G protein-coupled state of the D2 receptor,ie,its active
state.
76With partial D2 agonist properties it is conceived
as a dopamine system stabilizer: in high dopaminergic
states it acts as an antagonist,and in low dopaminergic
states it acts as an agonist.
77 This may explain why it is
unlikely to cause extrapyramidal side effects or prolactin
elevation even at high D2 receptor occupancy.
78-80
Aripiprazole also has high affinity for the D3 receptor
and is an antagonist at the 5-HT2a receptor.
81 It has only
moderate affinity to the adrenergic alpha-1 receptor and
histamine H1 receptor,and negligible affinity to the mus-
carinic receptor.
82 As a result, orthostatic hypotension
and antihistaminergic or anticholinergic adverse effects
are less likely to occur than with other atypicals.Also,
increases in mean QTc interval are not observed.Finally,
as hyperprolactinemia can contribute to osteoporosis,
aripiprazole’s lack of this side effect reduces this concern.
These pharmacodynamic features make aripiprazole
attractive for use in older patients.
A meta-analysis of the use of atypicals as augmentation
treatment for depression found pooled response rates of
57% vs 35% for placebo.
83 The meta-analysis utilized
data from 10 double-blind,placebo-controlled studies of
augmentation of an antidepressant with an atypical
antipsychotic agent. Augmentation with olanzapine,
risperidone,and quetiapine was found to be efficacious
for treatment-resistant depression.This meta-analysis did
not include data on aripiprazole or from geriatric sam-
ples.In part,the efficacy of atypicals in this context seems
to stem from their benefit for anxiety,
84,85 which is a
marker for poor outcomes in MDD.Their 5-HT2a recep-
tor antagonism would be expected to increase serotonin
and norepinephrine release,thus augmenting the effect
of SSRIs and SNRIs.
86,87 In the case of aripiprazole,anti-
depressant and antianxiety actions could also stem from
its D2 partial antagonism
88 or its high affinity for D3
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iety and depression in the context of the amygdala-pre-
frontal circuit, with amygdala hyperactivity coinciding
with prefrontal hypoactivity
89 and both coinciding with
imbalances in dopamine.
90 Aripiprazole, through its
dopamine partial agonism,may promote equilibrium in
this circuit and provide benefits for anxiety and depres-
sion.However,this neurobiological argument requires
further testing.
Two large,industry-initiated,placebo-controlled trials of
nongeriatric adults have recently demonstrated the effi-
cacy of aripiprazole as an augmentation treatment for
depression incompletely responsive to SSRIs and
SNRIs.
91,92 Based on these regulatory trials,the FDA has
approved an indication for the use of aripiprazole to aug-
ment SSRIs and SNRIs for treatment-resistant depres-
sion. The one published trial showed a higher rate of
remission (as measured with the Montgomery-Åsberg
Depression Rating Scale) in the aripiprazole group than
in the placebo group. Few adverse events leading to
about 3% discontinuation in each group.
91,92Two limita-
tions of this study were the short duration of the augmen-
tation trial (6 weeks) and the high placebo remission rate
(37%) suggesting that the criteria for treatment resis-
tance (failure to respond to one 8-week antidepressant
lead-in phase that did not maximize dosage) were not
stringent enough.
Aripiprazole has been examined preliminarily in LLD as
an augmentation for SSRI nonresponders,
93 and the
Pittsburgh group has examined its effect and tolerability
in 24 SNRI nonresponders
94 (data presented below).As
described below,these two small open-label studies have
similar results:50% of older nonresponders converted to
remitters,and adverse events requiring treatment cessa-
tion were infrequent. These preliminary results are
encouraging but, to our knowledge, no placebo-con-
trolled examination of aripiprazole for TRLLD has been
carried out.
Safety issues with atypicals in older adults
Atypicals have come under scrutiny due to the metabolic
disturbances they may cause and safety issues uncovered
in older patients with dementia.Weight gain and related
metabolic disturbances such as glucose intolerance and
dyslipidemia occur more frequently in psychiatric
patients than the general population,with the totality of
risk related not only to medication effects but to under-
lying characteristics of the patient population (eg,base-
line overweight and obesity, high fat/high caloric diet,
poor medical care).
95The Clinical Antipsychotic Trials of
Intervention Effectiveness (CATIE) confirmed other
reports demonstrating risks for metabolic disturbances
with atypicals,although that study did not examine arip-
iprazole.Among the atypicals,risk of weight gain,dyslipi-
demia,and diabetes is highest with clozapine and olan-
zapine;more modest weight gain is generally observed
with quetiapine and risperidone,along with lower insulin
resistance risk, variably lower dyslipidemia risk, and
largely negative if somewhat discrepant results concern-
ing diabetes risk.The lowest risk of weight gain,as well
as little or no risk for dyslipidemia or diabetes, is
observed with aripiprazole and ziprasidone.
95-97 These
metabolic risks have not been consistently reported in
the elderly, where some studies indicate little or no
weight gain,even on higher-risk agents (eg refs 98-100).
However,there are limited data in elderly samples,and
available reports that include a placebo group often find
weight loss,consistent with progressive reductions in lean
muscle mass.Thus,in elderly persons,measuring weight
gain alone with antipsychotics could miss treatment-
related increases in adiposity.Direct measures of adipos-
ity such as dual-energy X-ray absorptiometry (DEXA)
as well as sensitive and reliable measures of insulin resis-
tance,lipid metabolism,and glucose control,are needed
in research studies of these medications to examine
metabolic risk.
A meta-analysis found a higher mortality with atypicals
compared with placebo in older patients with dementia,
resulting in a black-box warning for the entire class of
atypicals.It remains unclear what the increased mortal-
ity resulted from,though possibilities include the sedat-
ing properties of these agents (leading to falls or aspira-
tion pneumonia), QT prolongation (leading to
arrhythmias and sudden cardiac death),venous throm-
boembolism leading to pulmonary embolism,and other
cardiovascular or cerebrovascular events.
101,102 It is
unknown whether these risks apply to nondemented
elderly patients.A third type of adverse event involves
extrapyramidal side effects and other (nonvascular) neu-
rological problems. Age-associated reductions in
dopamine and D2 receptors make the elderly more sen-
sitive to antipsychotics, although aripiprazole’s partial
agonism at the D2 receptor could reduce such effects.
Thus,a placebo-controlled clinical trial is needed to fur-
ther investigate the tolerability and safety of aripiprazole
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423augmentation in LLD.The lack of such a trial is a signif-
icant gap in our knowledge base.
In summary,TRLLD is a common and potentially dev-
astating condition,yet we have an extremely limited evi-
dence basis for its management.Clinicians do not have
data to guide them regarding which augmentation agent
to use, in whom, how, or with which risk:benefit ratio.
Needed is a randomized placebo-controlled trial to sup-
port the value of a modern pharmacologic treatment for
TRLLD,to establish a new approach to TRLLD,to lead
to a greater understanding of treatment response vari-
ability and ultimately to personalized treatment for LLD.
Also needed is a multidimensional approach to treat-
ment resistance, in which key clinical features in LLD
(anxiety,medical comorbidity,and executive dysfunction)
are examined as hypothesized moderators for augmen-
tation outcomes.An examination of genetic variability at
the drug target molecules,with a goal to predict those in
whom specific treatment strategies (eg,high-dose ven-
lafaxine,aripiprazole augmentation) are more robust is
also needed to personalize treatment.Finally,a detailed
examination of the sources of treatment resistance using
state-of-the-art pharmacokinetic methods is necessary.
For illustrative purposes, we now present work in
progress with aripiprazole as a candidate augmentation
strategy for incomplete response to antidepressant phar-
macotherapy.
Aripiprazole augmentation data: pilot study
and design of a controlled trial
To examine the acceptability, feasibility, and safety of
aripiprazole as an augmentation agent for incomplete
response in LLD,we carried out a 12-week open-label
pilot study in 24 elderly patients.
94 Patients aged 65+ with
current major depressive disorder,with an initial HAM-
D score ≥5 were first treated with escitalopram for 16
weeks.Those who failed to respond (HAM-D≥15,N=19)
or responded partially (HAM-D=11-14, N=5) were
switched to either duloxetine up to 120mg/d or venlafax-
ine up to 225 mg/day (depending on tolerability and prior
medication history) and treated for 12 weeks.Those with
partial or nonresponse to the SNRI were started on 2.5
mg/day of adjunctive aripiprazole,titrated weekly in 2.5-
mg increments to 15 mg,as tolerated and as needed to
reach remission.
The 24 subjects had a mean age of 74 (range 65 to 91);
58% were female;8% were African-American.Nineteen
of 24 (79%) patients completed all 12 weeks of augmen-
tation with aripiprazole,and 12/24 (50%) met criteria for
remission (defined as 2 consecutive weeks of HAM-
D≤10).
Tolerability and side effects
Three of 24 (13%) discontinued prior to week 12 due to
failure to improve or withdrawal of consent, and 2/24
(8%) discontinued due to side effects (one each:seda-
tion,akathisia).Side effects were also examined via the
UKU side effects scale.
103 Overall UKU scores showed a
decline (indicating fewer reports of somatic complaints
compared to baseline).However,the mean score of the
UKU-Neurologic subscale increased. Six of 24 (25%)
subjects had a positive score on the UKU-akathisia item
on at least one time point;however,in all but one case,
these were mild and/or transient.
We also examined metabolic changes and weight gain
during the 12-week period of pharmacotherapy augmen-
tation.One subject had a significant increase in lipids,and
none had a significant increase in blood sugar,suggesting
that metabolic effects were infrequent with aripiprazole.
Weight gain was highly variable:9/15 (60%) gained <2 kg
(mean [range] 0.8 [-0.7- 1.8]) while 6/15 (40%) gained >3
kg (mean [range] 4.7 [3.2-6.4]),suggesting that an exam-
ination of sources of weight gain variability would be use-
ful.Two possibilities from the literature are genetic vari-
ation at the 5-HT2C receptor (posited as the receptor
responsible for weight gain with aripiprazole) and base-
line body mass index (BMI).Also,we were not able to
determine whether weight gain represented an increase
in adiposity vs an increase in lean body mass with remis-
sion from depression.Thus, we determined that a con-
trolled study should include:(i) a more precise examina-
tion of changes in adiposity, including DEXA scans
which would provide quantitative measures of body fat;
(ii) an examination of moderators of weight gain (includ-
ing baseline BMI and 5-HT2C genotyping); and (iii) a
continuation phase,allowing longer duration to observe
weight changes.
Pilot study of continuation phase pharmacotherapy
Of the 24 participants who received acute-phase adjunc-
tive aripiprazole, 12 met study criteria for complete
response (remission) and entered continuation phase
pharmacotherapy,on an average daily dose of 10 mg of
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aripiprazole (as an adjunct to their primary antidepres-
sant pharmacotherapy).The 12 participants in the feasi-
bility study of continuation-phase pharmacotherapy had
a mean age of 72.7 (SD:6.2);9 were women,and 10 were
white (2 were African-American).
Outcomes
Depressive relapse during continuation-phase pharma-
cotherapy
Over a median duration of 27.6 weeks (range:2-106) of
continuation-phase combined pharmacotherapy (antide-
pressant + aripiprazole), none of the 12 participants
experienced relapse of a major depressive episode.
Retention
One of 12 participants was noncompliant with study pro-
cedure (due to respondent burden and other treatment
preferences) and exited the study.
Side effects
UKU side effect scores remained stable (9.4[3.2] at start
of continuation-phase pharmacotherapy [n = 12] and
7.9[2.8] at 6 months [n = 7]).No participant left the study
due to treatment-emergent adverse events.
Metabolic data
Body mass index was stable over 6 months (29.8 [6.1] at
start of continuation phase pharmacotherapy [n = 12]
and 30.1 [6.1] at 6 months [n = 7]).
Figure 1 depicts individual participants’ patterns of
change in the metabolic data between baseline and 6
months,after an overnight fast for glucose,triglyderides,
cholesterol,HDL,and LDL.In general,values were sta-
ble over time.One person each had a spike in glucose,
triglycerides,and cholesterol/LDL.After the 6-month fol-
low-up,this last person was started on a statin prescribed
by their primary care physician,who judged that the ben-
efit of continuing treatment with aripiprazole in the study
was substantial, and that metabolic changes could be
managed medically.
In general, glucose and triglycerides showed minimal
change, suggesting that aripiprazole does not cause
insulin resistance as do some other atypicals do (eg,olan-
zapine). In a comprehensive review of this topic,
Newcomer showed that generally a lipid signal with atyp-
icals will be seen in triglycerides;thus the lack of a signal
in these pilot data suggest that aripiprazole will be a safe
treatment in older adults with respect to metabolic
effects.
97We plan to closely control the collection proce-
dures in subjects,so that pre-post differences are not due
to variability in fasting,stasis-venous collection,etc.The
lack of clinically informative data on this in the elderly is
striking in light of the high cardiovascular mortality in
mentally ill persons generally and underscores the need
for this research.
104
These data from acute and continuation open pharma-
cotherapy illustrate three points.
1.Further investigation should evaluate both the benefits
and the costs (eg,adverse effects,metabolic changes) of
adjunctive aripiprazole pharmacotherapy,using a dou-
ble-blind,randomized,placebo-controlled design.
2.These data show the feasibility and safety of treating
participants (i) during acute-phase pharmacotherapy
(n=24),to determine change from incomplete to com-
plete response; and (ii) during continuation-phase
pharmacotherapy (n=12), to determine stability of
remission and rates of depressive relapse.
3.These data also underscore the importance of examin-
ing risks,as well as benefits,in a large randomized,dou-
ble-blind,placebo-controlled study.The cost-benefit
ratio and the ensuing clinical conclusions may be very
different when benefit and harm are conjointly consid-
ered,from what they are when benefit and harm are
considered separately (as the post-marketing experi-
ence with COX-2 inhibitors and oral hypoglycemic
agents teaches us,vis-à-vis heart disease).We believe
that this is the most appropriate approach scientifically
and ethically to a treatment study of frail older
depressed patients who have responded only partially
to antidepressant pharmacotherapy.
Our conclusions from this pilot study
1.In older adults with MDD having incomplete response
to an SSRI followed by an SNRI, remission was
obtained in 50% during aripiprazole augmentation.
2.In most subjects who remitted,the improvements in
depression were stable throughout 6-month continua-
tion pharmacotherapy.
3.Aripiprazole was well-tolerated, with a low rate of
dropout due to side effects and a high completion rate,but restlessness and weight gain were not uncommon.
Overall,a larger,placebo-controlled study is needed to
test hypotheses related to remission,tolerability,safety,
and outcome predictors.These pilot data support the
feasibility of such a trial. In Figure 2, we show the
design of a placebo-controlled randomized clinical trial
which we plan to conduct.
The planned trial calls for enrolling 500 patients aged 60
and older with major depressive disorder and treating
them openly for 12 weeks with venlafaxine XR (up to
225 mg/d) to prospectively determine incomplete
response (phase 1). Participants meeting criteria for
incomplete response estimated (n=200) will be randomly
assigned to receive either aripiprazole (2.5-15 mg/d;tar-
get dose:10 mg/d) or placebo augmentation of venlafax-
ine for 12 weeks (phase 2), with the goal of achieving
remission (Montgomery-Åsberg DRS<10 for two con-
secutive assessments).Those who remit in phase 2 will
receive continuation treatment,with the same double-
blinded intervention to which they were randomly
assigned (phase 3),for 12 weeks to determine the stabil-
ity of remission.Based on efficacy and tolerability data,
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Figure 1. Metabolic profile of individual patients (each indicated by a separate symbol) during continuation treatment with aripiprazole over a median
period of 6 months.
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M6we will estimate number needed to treat and number
needed to harm,providing a clinically informative esti-
mate of benefits and risks of aripiprazole augmentation
for TRLLD.
Conclusion
In summary, the public health importance of TRLLD
studies is great, but there are no data from controlled
studies to guide practice. Data are needed to not only
examine the overall efficacy of adjunctive treatments but
also examine in whom such treatments are most effica-
cious and safe,thus moving the treatment of LLD into
the arena of personalized medicine.❏
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Figure 2. Representation of proposed multisite study of aripiprazole (aripip) augmentation for treatment-resistant late-life depression. Venla, ven-
lafaxine
Phase 1 (N=500)
12 wk open-label
All subjects receive 6 wk venla
150mg/d, then nonremitters receive
6 wk venla 225 mg/d 
Phase 2 (N=200)
12 wk acute augmentation
Randomization of phase 1 venla
nonremitters
Venla 225 mg + placebo
Venla 225 mg + aripip
Aripip start 2.5 mg; titrate wkly
Target dose: 10 mg/d
Max. dose: 15 mg/d
Remission: MADRS<10 for at 
least two consecutive assessments
Ns assume 20% dropout & 50% remit in 
Phase 1: 50% remission with aripip vs
30% with placebo during Phase 2
Venla 225 mg + placebo
Venla 225 mg + aripip
Phase 3 (N=80)
12 wk continuation
Remitters in phase 2 stay on 
blinded treatment
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Respuesta incompleta en la depresión del
anciano: alcanzando la remisión 
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farmacoterapia antidepresiva de primera línea, aun
bajo condiciones terapéuticas óptimas. La depresión
resistente al tratamiento en el anciano aumenta el
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tivo, impone una mayor carga para los cuidadores
de la familia y aumenta el riesgo de mortalidad pre-
coz, incluyendo el suicidio. Alcanzar y mantener la
remisión es el objetivo primario del tratamiento,
pero hay una carencia de datos empíricos acerca del
mejor manejo de este tipo de depresión. Un estu-
dio piloto realizado por nuestro grupo con aripipra-
zol como potenciador en 24 respondedores incom-
pletos a una secuencia de farmacoterapia con ISRS
y antidepresivos duales encontró que el 50% remi-
tió en 12 semanas con la adición de aripiprazol, y
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famille proche et augmente le risque de décès pré-
coce y compris de suicide. Le premier but du traite-
ment est d’obtenir et de prolonger la rémission,
malgré l’absence de données empiriques sur la
meilleure façon de prendre en charge la DTRT.
Notre groupe a mis en place une étude pilote sur
l’ajout d’aripiprazole chez 24 répondeurs partiels
au traitement séquentiel par IRSS et IRSN et a
trouvé que 50 % des patients étaient en rémission
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